Generation of a human induced pluripotent stem cell line, BRCi004-A, derived from a patient with age-related macular degeneration.

Cell Differentiation Humans Induced Pluripotent Stem Cells Macular Degeneration / genetics

Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
05 2020
Historique:
received: 22 02 2020
revised: 19 03 2020
accepted: 27 03 2020
pubmed: 18 5 2020
medline: 22 6 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

Age-related macular degeneration (AMD) is a late-onset progressive blinding disease. We established human induced pluripotent stem cells (iPSCs) from an AMD patient. The generated iPSC line showed pluripotency markers and three-germ layer differentiation ability in vitro. This iPSC line will be useful for elucidating the pathomechanisms of and drug discovery for AMD.

Identifiants

DOI: 10.1016/j.scr.2020.101787 PMID: 32416577
pubmed: 32416577
pii: S1873-5061(20)30090-8
doi: 10.1016/j.scr.2020.101787
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101787

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Kazuma Kamata (K)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.

Yuki Otsuka (Y)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Keiko Imamura (K)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, 606-8507, Japan.

Akio Oishi (A)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Takayuki Kondo (T)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, 606-8507, Japan.

Mika Suga (M)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Ran Shibukawa (R)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Yasue Okanishi (Y)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.

Yukako Sagara (Y)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan.

Kayko Tsukita (K)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Tsutomu Yasukawa (T)

Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Hideaki Usui (H)

Department of Ophthalmology and Visual Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Keiko Muguruma (K)

Laboratory for Cell Asymmetry, RIKEN Center for Developmental Biology, Kobe, 650-0047, Japan; Department of iPS Cell Applied Medicine, Graduate School of Medicine, Kansai Medical University, Hirakata, 573-1010, Japan.

Akitaka Tsujikawa (A)

Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Haruhisa Inoue (H)

iPSC-based Drug discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. Electronic address: haruhisa.inoue@riken.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › Generation of a human induced pluripotent stem...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Generation of a human induced pluripotent stem...
questionsmedicales.fr › Cellules › Cellules souches › Cellules souches pluripotentes › Cellules souches pluripotentes induites › Generation of a human induced pluripotent stem...
questionsmedicales.fr › Maladies de l'oeil › Rétinopathies › Dégénérescence de la rétine › Dégénérescence maculaire › Generation of a human induced pluripotent stem...